Spots Global Cancer Trial Database for gvhd
Every month we try and update this database with for gvhd cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia | NCT00914628 | Acute Leukemia ... | HSV-Tk T-cell depleted... | 18 Years - | AGC Biologics S.p.A. | |
| The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell Transplantation | NCT02976558 | Hematological N... Graft-Versus-Ho... Depression Stem Cell Trans... Quality of Life Leukemia | Clown theatrica... Acupuncture Music Therapy T... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | NCT03680092 | GVHD Hematologic Neo... | Cyclophosphamid... abatacept Methotrexate Tacrolimus | 18 Years - | University of California, San Diego | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) | NCT00693927 | Hematologic Mal... | Unmanipulated P... CD8-depleted PB... | - 70 Years | University of Liege | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor | NCT06083129 | GVHD | Grafalon Thymoglobulin | 50 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | NCT00800839 | Hematologic Dis... Leukemia Lymphoma Myeloma | Busulfan Fludarabine Cyclophosphamid... | 6 Months - 75 Years | M.D. Anderson Cancer Center | |
| Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT | NCT03066466 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... | Atorvastatin Methotrexate Tacrolimus | 18 Years - 75 Years | Loyola University | |
| Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | NCT00966810 | Philadelphia Ch... | Stem cell trans... | 18 Years - 65 Years | Rambam Health Care Campus | |
| Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) | NCT01379209 | Graft Versus Ho... | RGI-2001 Calcineurin Inh... Allogeneic Hema... Conditioning Re... Allogeneic Bone... Methotrexate Mofetil Mycophe... sirolimus | 18 Years - | Regimmune Corporation | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | NCT02169505 | Lymphoma | Brentuximab Ved... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia | NCT04033627 | Relapsed Pediat... Acute Graft-Ver... Relapsed Pediat... | In Vitro T cell... | 2 Months - 18 Years | Shanghai Children's Medical Center | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | NCT05800210 | Acute Lymphobla... Acute Myeloid L... Juvenile Myelom... Myelodysplastic... Chronic Myeloid... Lymphoma, Non-H... Lymphoma, Hodgk... | Miltenyi CliniM... | 6 Months - 39 Years | University of Florida | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| MSC and HSC Coinfusion in Mismatched Minitransplants | NCT01045382 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myeloproliferat... Myelodysplastic... Multiple Myelom... Leukemia, Lymph... Hodgkin's Disea... Lymphoma, Non-H... | Mesenchymal ste... Isotonic soluti... | - 75 Years | University of Liege | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning | NCT03852407 | Acute Myeloid L... Myelodysplastic... Chronic Myeloid... Myeloproliferat... Myeloproliferat... Acute Lymphoid ... Multiple Myelom... Chronic Lymphoi... Non Hodgkin Lym... Hodgkin Lymphom... | Thymoglobulin Melphalan Fludarabine Cyclophosphamid | 18 Years - 75 Years | University of Liege | |
| Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation | NCT02828878 | Hematological M... | Allogeneic MPBC... | 18 Years - 70 Years | Cellect Biotechnology | |
| Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia | NCT00914628 | Acute Leukemia ... | HSV-Tk T-cell depleted... | 18 Years - | AGC Biologics S.p.A. | |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer | NCT02999854 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | ATIR101 Cyclophosphamid... T-cell depleted... T-cell replete ... | 18 Years - 70 Years | Kiadis Pharma | |
| Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT | NCT03395860 | Graft-versus-ho... Prophylaxis | ATG | 14 Years - 70 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | NCT03088709 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... Non-hodgkin Lym... Chronic Lymphoc... | Cyclophosphamid... Tacrolimus Mycophenolate m... Haploidentical ... | 16 Years - 90 Years | Loyola University | |
| Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases | NCT00038857 | Leukemia Lymphoma | Megadose of CD3... Melphalan Thiotepa Fludarabine Rabbit ATG | - 55 Years | M.D. Anderson Cancer Center | |
| Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor | NCT06083129 | GVHD | Grafalon Thymoglobulin | 50 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant | NCT00476177 | Hematologic Mal... | Infusion of don... Infusion of don... | 18 Years - | Dana-Farber Cancer Institute | |
| Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation | NCT01517347 | Leukemia | Interleukin-2 | 15 Years - 65 Years | Peking University People's Hospital | |
| Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) | NCT01295710 | GVHD Adult Acute Mye... Adult Acute Lym... Myelodysplastic... | US-ATG-F Placebo | 18 Years - 65 Years | Neovii Biotech | |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. | NCT02849886 | Graft Versus Ho... Hematological M... | T lymphocytes i... Dimerizer drug ... | 40 Years - 55 Years | Centre Hospitalier Universitaire de Besancon | |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies | NCT00943293 | Preleukemia Myeloproliferat... Lymphoma Myeloma Graft Versus Ho... | Fludarabine Melphalan Campath | 18 Years - | University of Chicago | |
| Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis | NCT01860170 | Hematological M... | Cohort 1-Bortez... Cohort 2-Bortez... Cohort 3-Bortez... | 18 Years - | Spectrum Health Hospitals | |
| Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | NCT00966810 | Philadelphia Ch... | Stem cell trans... | 18 Years - 65 Years | Rambam Health Care Campus | |
| Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation | NCT00369226 | Hematologic Mal... | Bortezomib (Vel... Tacrolimus Methotrexate blood stem cell... | 18 Years - | Dana-Farber Cancer Institute | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD | NCT00524784 | Graft Versus Ho... Hematological M... | ApoCell | 18 Years - 60 Years | Hadassah Medical Organization | |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. | NCT02849886 | Graft Versus Ho... Hematological M... | T lymphocytes i... Dimerizer drug ... | 40 Years - 55 Years | Centre Hospitalier Universitaire de Besancon | |
| Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | NCT00473551 | Leukemia Lymphoma Myeloma | Rituximab Cyclophosphamid... Fludarabine Mesna Radiation Treat... Stem Cell Trans... Sirolimus Anti-third Part... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | NCT00800839 | Hematologic Dis... Leukemia Lymphoma Myeloma | Busulfan Fludarabine Cyclophosphamid... | 6 Months - 75 Years | M.D. Anderson Cancer Center | |
| Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders | NCT03198234 | AML - Acute Mye... MDS (Myelodyspl... Mixed Phenotype... NHL - Non-Hodgk... Hodgkin's Lymph... ALL | T-allo10 | 3 Years - 45 Years | Stanford University | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | NCT05675930 | Graft-Versus-Ho... GVHD Undefined | Photobiomodulat... Placebo sham de... | 4 Years - | Memorial Sloan Kettering Cancer Center | |
| Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation | NCT01020175 | Acute Leukemia Chronic Myeloge... Myelodysplastic... | Bone marrow tra... Peripheral bloo... | 18 Years - 55 Years | European Society for Blood and Marrow Transplantation | |
| The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell Transplantation | NCT02976558 | Hematological N... Graft-Versus-Ho... Depression Stem Cell Trans... Quality of Life Leukemia | Clown theatrica... Acupuncture Music Therapy T... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | NCT00144677 | Acute Myelogeno... Graft Versus Ho... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | sirolimus tacrolimus | 18 Years - 55 Years | Dana-Farber Cancer Institute | |
| Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation | NCT01020175 | Acute Leukemia Chronic Myeloge... Myelodysplastic... | Bone marrow tra... Peripheral bloo... | 18 Years - 55 Years | European Society for Blood and Marrow Transplantation | |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | NCT05088356 | Allogeneic Hema... Advanced Hemato... Acute Leukemia Chronic Myeloge... Myelodysplastic... Myeloproliferat... | Purified regula... Fludarabine Melphalan CliniMACS CD34 ... Tacrolimus Cyclophosphamid... Plerixafor Filgrastim gran... Thiotepa Mycophenolate M... Ruxolitinib | 18 Years - 75 Years | Stanford University | |
| Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | NCT00800839 | Hematologic Dis... Leukemia Lymphoma Myeloma | Busulfan Fludarabine Cyclophosphamid... | 6 Months - 75 Years | M.D. Anderson Cancer Center | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | NCT03680092 | GVHD Hematologic Neo... | Cyclophosphamid... abatacept Methotrexate Tacrolimus | 18 Years - | University of California, San Diego | |
| Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB) | NCT01235468 | Umbilical Cord ... Stem Cell Trans... Hematological M... | ex vivo expansi... | 18 Years - 70 Years | Sheba Medical Center | |
| Allo HSCT Using RIC and PTCy for Hematological Diseases | NCT05805605 | Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis | Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M... | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Intra-Osseous Co-Transplant of UCB and hMSC | NCT02181478 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Myelofibrosis Relapsed Non-Ho... Refractory Non-... Hodgkin Lymphom... Refractory Hodg... Relapsed Chroni... Refractory Chro... Lymphoid Malign... Chronic Myeloge... | cyclophosphamid... fludarabine pho... total-body irra... cyclosporine mycophenolate m... umbilical cord ... mesenchymal ste... | 18 Years - 75 Years | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
